

## A Novel Bispecific Antibody Targeting CD3 and CD19

<b>Drug Name</b>	***0111
<b>Description</b>	A bispecific antibody targeting CD3 and CD19 is in preclinical studies for the treatment of acute lymphocytic leukemia and lymphoma.
<b>Target</b>	CD3; CD19
<b>Drug Modality</b>	Antibody
<b>Indication</b>	Acute Lymphocytic Leukemia; Lymphoma
<b>Product Category</b>	Cancer Immunotherapy
<b>Mechanism of Action</b>	Anti-CD19; Anti-CD3
<b>Status</b>	Preclinical
<b>Patent</b>	Granted

### More Detail Available Upon Request

We look forward to hearing from you.